Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fees Would Fund Safety Oversight Throughout Product Life Cycles

This article was originally published in The Pink Sheet Daily

Executive Summary

PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.

You may also be interested in...



Nearly Half Of User Fees Should Target Post-market Actions – FDA Draft Plan

Spending on various safety initiatives would remain stable over five years; final plan is due by year end.

Nearly Half Of User Fees Should Target Post-market Actions – FDA Draft Plan

Spending on various safety initiatives would remain stable over five years; final plan is due by year end.

FDA To Respond To IoM’s Rx Safety Recommendations

Commissioner von Eschenbach will detail how FDA plans to improve its oversight of drug risk issues.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel